NewsHK
SERB Pharmaceuticals has agreed to acquire exclusive development and commercialization rights to Idefirix® (Imlifidase) from Swedish biotech Hansa Biopharma AB (Nasdaq Stockholm: HNSA) for €115 million, the companies announced in Brussels on May 20, 2026.
The transaction transfers authority over the asset across a broad stretch of Western and Northern Europe as well as the Middle East and North Africa, consolidating commercial and development responsibility under a single operator across those markets.
Geographic Reach of the Agreement The territories covered by the deal span the European Union, the United Kingdom, Switzerland, Norway, Liechtenstein, and Iceland, alongside the MENA region.
That footprint encompasses some of the world's most rigorously regulated pharmaceutical markets, where reimbursement frameworks and multi-jurisdiction approval requirements can shape commercial outcomes as decisively as clinical performance.
Keep reading